Author Topic: (Abst.) Effect of switching from Tysabri to moderate- vs. high-efficacy DMT in clinical practice  (Read 89 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest

From Neurology Clinical Practice (February 12, 2020), "Effect of switching from natalizumab to moderate- vs. high-efficacy DMT  in clinical practice"

https://cp.neurology.org/content/early/2020/02/12/CPJ.0000000000000809
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
More on this from Medscape (May 27, 2020)--"Natalizumab switch to moderate-efficacy DMT  increases disability risk":


https://www.medscape.com/viewarticle/931195




MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics